Get updates delivered to you daily. Free and customizable.
UPI News
Study shows shift in GLP-1 drug use for obesity, not diabetes
By Dennis Thompson, HealthDay News,
15 hours ago
The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.
The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds. Photo by Adobe Stock/HealthDay News
New prescriptions for these drugs have doubled among people who have obesity but not diabetes, investigators found.
As a result, drug shortages have triggered a drop in new prescriptions for Type 2 diabetes, even though Ozempic and Mounjaro were initially developed as diabetes drugs, the researchers said.
Both drugs were later approved for weight loss under different brand names, Wegovy and Zepbound .
"Essentially, after the medication was approved for obesity... use took off so quickly that we lost control and vision of how fast people were picking up these medications," said lead researcher Dr. Ali Rezaie , medical director of the Cedars-Sinai GI Motility Program.
For the study, researchers analyzed the medical data of about 45 million Americans between 2011 and 2023.
About 1 million people became new GLP-1 users during that period in time, results show. Researchers classified them based on whether they had diabetes, obesity or some other related medical condition.
GLP-1 drugs work by adjusting a person's hormone levels and suppressing appetite.
Semaglutide -- the drug sold as Ozempic and Wegovy -- is being prescribed disproportionately to females, Whites, and those with a BMI of 30 or more, indicating obesity, results show.
"This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift," said lead researcher Dr. Yee Hui Yeo , a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai Medical Center in Los AnGeles.
"However, it also raises concerns about potential medication shortages and the need to ensure that patients with diabetes still have access to these treatments," Yeo said in a Cedars-Sinai news release.
Get updates delivered to you daily. Free and customizable.
Welcome to NewsBreak, an open platform where diverse perspectives converge. Most of our content comes from established publications and journalists, as well as from our extensive network of tens of thousands of creators who contribute to our platform. We empower individuals to share insightful viewpoints through short posts and comments. It’s essential to note our commitment to transparency: our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. We strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation. Join us in shaping the news narrative together.
Comments / 0